AAPL 209.68 -3.3644% MSFT 378.77 -1.1741% NVDA 115.58 -0.1382% GOOGL 162.76 -2.6031% GOOG 164.73 -2.5266% AMZN 193.89 -2.514% META 590.64 -4.6678% AVGO 191.36 -1.4776% LLY 801.65 -2.4591% TSLA 240.68 -2.9868% TSM 171.59 -3.1495% V 328.55 -1.2889% JPM 225.19 -1.1891% UNH 481.52 0.0852% NVO 75.89 1.4708% WMT 84.5 -0.8216% LVMUY 129.76 -2.7942% XOM 108.67 -0.4215% LVMHF 655.0 -2.0693% MA 519.83 -0.9168%
Last update at 2025-03-13T20:10:00Z
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%
Fri 07 Mar 25, 07:58 PMBio-Rad (BIO) International Revenue Performance Explored
Wed 26 Feb 25, 02:15 PMHSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
Tue 25 Feb 25, 04:28 PMVeracyte Stock Falls Despite Q4 Earnings and Revenue Beat
Tue 25 Feb 25, 01:00 PMGlobus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
Fri 21 Feb 25, 01:17 PMEXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
Thu 20 Feb 25, 01:06 PMPenumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
Wed 19 Feb 25, 12:14 PMIndia's market regulator proposes steps to secure investors' trading accounts
Tue 18 Feb 25, 02:24 PMMedtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
Tue 18 Feb 25, 02:18 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -4704.27300M | 5438.15M | 4907.64M | 2261.08M | 507.36M |
| Minority interest | - | - | - | - | - |
| Net income | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 361.00M |
| Selling general administrative | 827.83M | 879.57M | 800.27M | 824.62M | 834.78M |
| Selling and marketing expenses | - | - | - | - | 1.49M |
| Gross profit | 1567.33M | 1640.66M | 1437.82M | 1257.00M | 1224.36M |
| Reconciled depreciation | 137.30M | 133.80M | 138.10M | 134.20M | 138.10M |
| Ebit | 482.62M | 489.43M | 410.96M | 229.66M | 228.47M |
| Ebitda | 664.49M | 650.01M | 573.57M | 389.99M | 366.55M |
| Depreciation and amortization | 181.87M | 160.58M | 162.62M | 160.33M | 138.09M |
| Non operating income net other | 44.78M | 24.02M | 22.72M | 23.85M | 33.73M |
| Operating income | 482.62M | 489.43M | 410.96M | 229.66M | -108.64100M |
| Other operating expenses | 2319.63M | 2433.11M | 2134.67M | 2082.00M | 2098.24M |
| Interest expense | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M |
| Tax provision | -1076.73800M | 1192.25M | 1101.37M | 502.41M | 147.04M |
| Interest income | 58.00M | 4921.94M | 4491.39M | 30.50M | 26.60M |
| Net interest income | 19.89M | -1.55100M | -21.86100M | 7.08M | 2.64M |
| Extraordinary items | - | - | - | - | 49.00M |
| Non recurring | - | - | - | - | 292.51M |
| Other items | - | - | - | - | - |
| Income tax expense | -1076.73800M | 1192.25M | 1101.37M | 502.41M | 146.36M |
| Total revenue | 2802.25M | 2922.55M | 2545.63M | 2311.66M | 2290.11M |
| Total operating expenses | 1084.71M | 1151.23M | 1026.87M | 1027.34M | 1032.49M |
| Cost of revenue | 1234.92M | 1281.88M | 1107.80M | 1054.66M | 1065.75M |
| Total other income expense net | -5186.88900M | 4948.72M | 4496.68M | 2031.42M | 339.45M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 365.61M |
| Net income applicable to common shares | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 365.61M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 12299.07M | 13501.67M | 17775.79M | 12972.62M | 8008.86M |
| Intangible assets | 320.48M | 332.15M | 253.94M | 199.50M | 145.53M |
| Earning assets | - | - | - | - | - |
| Other current assets | 171.65M | 147.78M | 117.83M | 101.48M | 113.27M |
| Total liab | 3557.94M | 3886.41M | 4108.66M | 3092.68M | 2253.80M |
| Total stockholder equity | 8741.13M | 9615.25M | 13667.13M | 9879.94M | 5755.06M |
| Deferred long term liab | - | 1770.48M | 3059.08M | 2076.78M | 997.79M |
| Other current liab | 302.04M | 186.20M | 210.67M | 224.94M | 158.49M |
| Common stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00300M |
| Capital stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00300M |
| Retained earnings | 9260.63M | 9898.20M | 13507.24M | 9268.01M | 5470.78M |
| Other liab | - | 1966.39M | 3417.21M | 2448.88M | 1158.71M |
| Good will | 413.60M | 406.49M | 347.34M | 291.92M | 264.13M |
| Other assets | - | 94.60M | 0.08M | 0.01M | 40.26M |
| Cash | 403.97M | 434.21M | 470.78M | 662.21M | 660.67M |
| Cash and equivalents | - | 434.21M | 470.78M | 662.21M | 660.67M |
| Total current liabilities | 522.80M | 568.71M | 680.94M | 631.54M | 905.50M |
| Current deferred revenue | 35759.00M | 52.21M | 50.85M | 42.47M | 33.73M |
| Net debt | 1001.63M | 763.97M | -459.78000M | -648.14900M | -220.92100M |
| Short term debt | 40.38M | 0.47M | 0.49M | 1.80M | 426.17M |
| Short long term debt | 0.49M | 0.47M | 0.49M | 1.80M | 426.17M |
| Short long term debt total | 1405.44M | 1198.18M | 11.00M | 14.06M | 439.75M |
| Other stockholder equity | -183.46100M | 183.87M | 335.44M | 329.47M | 371.62M |
| Property plant equipment | - | 498.61M | 695.75M | 491.37M | 499.34M |
| Total current assets | 3048.33M | 3157.98M | 1989.09M | 2139.84M | 2180.16M |
| Long term investments | 7698.07M | 8830.89M | 14387.01M | 9561.14M | 4638.20M |
| Net tangible assets | - | 9208.76M | 13065.85M | 9879.94M | 5755.06M |
| Short term investments | 1203.33M | 1362.02M | 404.69M | 334.47M | 459.53M |
| Net receivables | 489.02M | 494.64M | 423.54M | 419.42M | 392.67M |
| Long term debt | 1199.05M | 1197.72M | 10.51M | 12.26M | 13.58M |
| Inventory | 780.52M | 719.32M | 572.24M | 622.25M | 554.01M |
| Accounts payable | 144.62M | 329.83M | 418.93M | 362.33M | 287.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -336.03800M | -466.82200M | -175.55300M | 282.46M | -87.34800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00300M | 0.00300M | 0.00200M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 9898.20M | 13507.24M | 9268.01M | 5470.78M |
| Treasury stock | - | -263.58600M | -106.29000M | -99.90700M | -38.39700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 94.45M | -1770386.40100M | -3058977.33100M | -2076698.27700M | -997707.36400M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 9250.74M | 10343.69M | 15786.71M | 10832.78M | 5828.70M |
| Capital lease obligations | 205.86M | 189.93M | 212.37M | 211.63M | 211.38M |
| Long term debt total | - | 1197.72M | 10.51M | 12.26M | 13.58M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -110.54100M | -994.21100M | -538.17100M | 119.60M | -119.30400M |
| Change to liabilities | - | -1335.80000M | 1152.20M | 1103.60M | 460.80M |
| Total cashflows from investing activities | - | -1207.59300M | -784.43800M | -60.25000M | -208.88900M |
| Net borrowings | - | 1185.71M | -3.02000M | -426.93800M | -1.12900M |
| Total cash from financing activities | -425.64700M | 973.58M | -55.42900M | -523.04100M | -22.75800M |
| Change to operating activities | - | -26.80000M | 13.93M | 51.68M | 73.50M |
| Net income | -637.32400M | -3627.53500M | 4245.90M | 3806.27M | 1758.67M |
| Change in cash | -30.17500M | -36.58900M | -195.98200M | 4.46M | 228.49M |
| Begin period cash flow | 434.54M | 471.13M | 667.12M | 662.65M | 434.16M |
| End period cash flow | 404.37M | 434.54M | 471.13M | 667.12M | 662.65M |
| Total cash from operating activities | 374.94M | 194.45M | 656.52M | 575.33M | 457.90M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 192.40M | 137.30M | 133.80M | 138.13M | 134.24M |
| Other cashflows from investing activities | - | -100.60000M | -658.92200M | -80.93100M | 0.13M |
| Dividends paid | 100101.00M | 68184.00M | 35282.00M | 20.20M | 3831.00M |
| Change to inventory | -46.30000M | -158.80000M | 46.10M | -52.10000M | 24.20M |
| Change to account receivables | 11.40M | -87.40000M | -20.40000M | -15.00000M | 1.60M |
| Sale purchase of stock | -428.72800M | -215.67900M | -49.99800M | -100.00400M | -28.00000M |
| Other cashflows from financing activities | 3.55M | -212.13400M | -2.41100M | 3.90M | 5.88M |
| Change to netincome | - | 5254.73M | -3776.37800M | -3457.81500M | -2031.17800M |
| Capital expenditures | 156.68M | 114.16M | 120.80M | 98.92M | 98.53M |
| Change receivables | - | 68.18M | 35.28M | 21.49M | 31.67M |
| Cash flows other operating | - | 126.26M | 621.24M | 553.84M | 426.22M |
| Exchange rate changes | - | - | -12.63600M | 12.43M | 2.24M |
| Cash and cash equivalents changes | - | -39.57000M | -195.98200M | 4.46M | 228.49M |
| Change in working capital | -127.63300M | -407.03800M | 13.93M | 51.68M | 55.39M |
| Stock based compensation | 61.30M | 60.90M | 51.20M | 41.60M | 35.60M |
| Other non cash items | 1078.60M | 5272.42M | -3737.11400M | -3420.74400M | -1490.40800M |
| Free cash flow | 218.26M | 80.29M | 535.72M | 476.41M | 359.37M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIO Bio-Rad Laboratories Inc |
-6.14 2.44% | 245.01 | - | 30.40 | 3.67 | 1.29 | 3.64 | -13.0746 |
| ABT Abbott Laboratories |
-0.39 0.30% | 129.89 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.18 0.05% | 363.66 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.82 0.90% | 92.33 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-1.05 1.09% | 95.37 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
| Name | Title | Year Born |
|---|---|---|
| Mr. Norman D. Schwartz | Chairman, CEO & Pres | 1950 |
| Mr. Ilan Daskal | Exec. VP & CFO | 1966 |
| Dr. Andrew J. Last Ph.D. | Exec. VP & COO | 1960 |
| Mr. Michael Crowley | Exec. VP of Global Commercial Operations | 1962 |
| Ms. Dara Grantham Wright | Exec. VP & Pres of Clinical Diagnostics Group | 1976 |
| Mr. Ajit Ramalingam | Sr. VP & Chief Accounting Officer | 1973 |
| Mr. Yong Chung | VP of Investor Relations | NA |
| Mr. Timothy S. Ernst | Exec. VP, Gen. Counsel & Sec. | 1960 |
| Colleen Corey | Sr. VP of Global HR | NA |
| Lee Boyd | Sr. VP of Global Commercial Operations - Asia Pacific | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...